Drug Displays Potential in Treating Lung Symptoms of Systemic Sclerosis
Myriams-Fotos / Pixabay

Drug Displays Potential in Treating Lung Symptoms of Systemic Sclerosis

According to a story from Boehringer Ingelheim Pharmaceuticals, Inc., the company has recently announced positive results from a phase 3 clinical trial testing the company's drug nintedanib (marketed as Ofev)…

Continue Reading Drug Displays Potential in Treating Lung Symptoms of Systemic Sclerosis
Cognitive Bias in Idiopathic Pulmonary Fibrosis Management and Steps We Can Take to Avoid It
Source: Pixabay.com

Cognitive Bias in Idiopathic Pulmonary Fibrosis Management and Steps We Can Take to Avoid It

Cedric Rutland, a pulmonologist at Pacific Pulmonary Medical Group has shared his experience, research, and thoughts on cognitive bias in an effort to spread awareness for the issue, and hopefully,…

Continue Reading Cognitive Bias in Idiopathic Pulmonary Fibrosis Management and Steps We Can Take to Avoid It

Orphan Drug Designation Granted for Potential Duchenne Muscular Dystrophy Treatment

For years FibroGen has been investigating a drug called pamrevlumab. They believe it could be an effective treatment for Duchenne muscular dystrophy (DMD), pancreatic cancer, and idiopathic pulmonary fibrosis (IPF).…

Continue Reading Orphan Drug Designation Granted for Potential Duchenne Muscular Dystrophy Treatment

Biomarker Identified Which Can Determine Severity of Idiopathic Pulmonary Fibrosis

Nigam Shah and Purvesh Khatri, professors at Stanford University, along with graduate student Madeleine Scott have just announced results from a research study which could be pivotal for those living…

Continue Reading Biomarker Identified Which Can Determine Severity of Idiopathic Pulmonary Fibrosis

New Research for Idiopathic Pulmonary Fibrosis to Investigate Genomic Cause of Disease

Idiopathic pulmonary fibrosis (IPF) is a rare condition with no known cause and no effective treatments besides a lung transplant. Current therapies focus on slowing progression of the disease but…

Continue Reading New Research for Idiopathic Pulmonary Fibrosis to Investigate Genomic Cause of Disease

Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need

According to a story from finanznachrichten.de, biotechnology companies are starting to set their sights on treating deadly diseases that are lacking effective treatment options, including some diseases that are considered…

Continue Reading Biotech Companies are Increasingly Focused on Deadly Diseases With Significant Unmet Need
FDA Accepts IND Application for Idiopathic Pulmonary Fibrosis Drug
rawpixel / Pixabay

FDA Accepts IND Application for Idiopathic Pulmonary Fibrosis Drug

According to a press release from X-Rx Inc., a privately-held American biotechnology company, the Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for X-165, an…

Continue Reading FDA Accepts IND Application for Idiopathic Pulmonary Fibrosis Drug

Vogmask Offers a Stylish Face Mask for Those Living with Immunodeficiencies

Vogmask is a San Francisco, California based company founded in 2011. They create stylish facial masks to protect wearers from inhalation of particulate and allergens. These types of masks can…

Continue Reading Vogmask Offers a Stylish Face Mask for Those Living with Immunodeficiencies

Research in Humans Promote Findings for Deadly Age-Related Disease Treatment

A January 4th post by the Lancet's EBioMedicine headlined the first-in-human pilot study results published by UT Health San Antonio in collaboration with the Mayo Clinic and the Wake Forest School…

Continue Reading Research in Humans Promote Findings for Deadly Age-Related Disease Treatment
Pliant Announces Phase 1 Clinical Study Evaluating Anti-Fibrotic Agent PLN-74809
Source: Pixabay

Pliant Announces Phase 1 Clinical Study Evaluating Anti-Fibrotic Agent PLN-74809

Pliant Therapeutics, Inc., a biotechnology company specializing in developing and commercializing treatments for fibrotic diseases, announced on January 3, 2019 through PRNewswire, that it has initiated a Phase 1 first-in-human…

Continue Reading Pliant Announces Phase 1 Clinical Study Evaluating Anti-Fibrotic Agent PLN-74809

Unique Class of Drugs Shows Potential in Treating Idiopathic Pulmonary Fibrosis

According to a story from Medical Xpress, a collaborative team of scientists from UT Health San Antonio, the Mayo Clinic, and the Wake Forest School of Medicine, have recently released…

Continue Reading Unique Class of Drugs Shows Potential in Treating Idiopathic Pulmonary Fibrosis
The First Patient Has Been Dosed in a Study of a Drug For Idiopathic Pulmonary Fibrosis
kalhh / Pixabay

The First Patient Has Been Dosed in a Study of a Drug For Idiopathic Pulmonary Fibrosis

The first patient has been dosed in a new clinical trial of an investigational drug for idiopathic pulmonary fibrosis. The drug, called GLPG1205, is being developed by Galapagos, and you…

Continue Reading The First Patient Has Been Dosed in a Study of a Drug For Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Patients and Advocates Call for Better Care in Wales
blickpixel / Pixabay

Idiopathic Pulmonary Fibrosis Patients and Advocates Call for Better Care in Wales

According to a story from BBC, John Mason, age 80, is one of over 2,000 people in Wales who currently have idiopathic pulmonary fibrosis (IPF), a rare and ultimately lethal…

Continue Reading Idiopathic Pulmonary Fibrosis Patients and Advocates Call for Better Care in Wales
The NIH Has Granted $8.9 million to Researchers Investigating a Drug For Idiopathic Pulmonary Fibrosis
kalhh / Pixabay

The NIH Has Granted $8.9 million to Researchers Investigating a Drug For Idiopathic Pulmonary Fibrosis

The National Institutes of Health (NIH) have granted the University of Alabama at Birmingham $8.9 million to fund research into an investigational drug for idiopathic pulmonary fibrosis. You can read…

Continue Reading The NIH Has Granted $8.9 million to Researchers Investigating a Drug For Idiopathic Pulmonary Fibrosis
Scientists Have Managed to Create a Mouse Model for Idiopathic Pulmonary Fibrosis
Free-Photos / Pixabay

Scientists Have Managed to Create a Mouse Model for Idiopathic Pulmonary Fibrosis

According to a story from EurakAlert!, a group of researchers from the University of Pennsylvania School of Medicine have achieved a major breakthrough for idiopathic pulmonary fibrosis research that will…

Continue Reading Scientists Have Managed to Create a Mouse Model for Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis Foundation Launches New PF Health App: Connect Patients to Resources, Providers and Researchers

CHICAGO, July 19, 2018 – The Pulmonary Fibrosis Foundation (PFF) and monARC Bionetworks have partnered to create the mobile app, PF Health, for individuals living with pulmonary fibrosis (PF).  PF Health, now available on Apple App Store (iOS 9.0 or…

Continue Reading Pulmonary Fibrosis Foundation Launches New PF Health App: Connect Patients to Resources, Providers and Researchers
This New Program Can Help Make Life Easier for Rare Disease Patients
geraldoswald62 / Pixabay

This New Program Can Help Make Life Easier for Rare Disease Patients

According to a story from CheckOrphan, Express Scripts has prepared a Rare Conditions Care Value (RCCV) program. This program is designed to help make the diagnosis and treatment process for…

Continue Reading This New Program Can Help Make Life Easier for Rare Disease Patients
Express Scripts Makes Diagnosis Easier with Second Opinion
Source: Pixabay

Express Scripts Makes Diagnosis Easier with Second Opinion

According to PRNewswire, Express Scripts announced a new program to benefit people living with rare diseases on May 31st. The program, called Second Opinion is part of the company’s larger…

Continue Reading Express Scripts Makes Diagnosis Easier with Second Opinion
Close Menu